Improving the Efficacy of Regulatory T Cell Therapy

被引：0
作者：
Paulien Baeten
Lauren Van Zeebroeck
Markus Kleinewietfeld
Niels Hellings
Bieke Broux
机构：
[1] Biomedical Research Institute,Neuro
[2] Hasselt University,Immune Connections and Repair Lab, Department of Immunology and Infection
[3] University MS Center,VIB Laboratory of Translational Immunomodulation, Center for Inflammation Research (IRC), Department of Immunology and Infection
[4] Biomedical Research Institute,Department of Internal Medicine
[5] Hasselt University,undefined
[6] Cardiovascular Research Institute Maastricht,undefined
[7] Maastricht University,undefined
来源：
Clinical Reviews in Allergy & Immunology | 2022年 / 62卷
关键词：
Regulatory T cells; Cell therapy; Autoimmunity; COVID-19; Gene editing; RNA interference;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Autoimmunity is caused by an unbalanced immune system, giving rise to a variety of organ-specific to system disorders. Patients with autoimmune diseases are commonly treated with broad-acting immunomodulatory drugs, with the risk of severe side effects. Regulatory T cells (Tregs) have the inherent capacity to induce peripheral tolerance as well as tissue regeneration and are therefore a prime candidate to use as cell therapy in patients with autoimmune disorders. (Pre)clinical studies using Treg therapy have already established safety and feasibility, and some show clinical benefits. However, Tregs are known to be functionally impaired in autoimmune diseases. Therefore, ex vivo manipulation to boost and stably maintain their suppressive function is necessary when considering autologous transplantation. Similar to autoimmunity, severe coronavirus disease 2019 (COVID-19) is characterized by an exaggerated immune reaction and altered Treg responses. In light of this, Treg-based therapies are currently under investigation to treat severe COVID-19. This review provides a detailed overview of the current progress and clinical challenges of Treg therapy for autoimmune and hyperinflammatory diseases, with a focus on recent successes of ex vivo Treg manipulation.
引用
收藏
页码：363 / 381
页数：18
相关论文
共 976 条
  • [1] Trzonkowski P(2009)First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells Clin Immunol 133 22-26
  • [2] Bieniaszewska M(2018)Regulatory T-cells: potential regulator of tissue repair and regeneration Front Immunol 9 585-680
  • [3] Juscinska J(2017)Regulatory T cells promote myelin regeneration in the central nervous system Nat Neurosci 20 674-1089
  • [4] Dobyszuk A(2015)A distinct function of regulatory T cells in tissue protection Cell 162 1078-1451
  • [5] Krzystyniak A(2014)Foxp3+ regulatory T cells promote lung epithelial proliferation Mucosal Immunol 7 1440-1295
  • [6] Marek N(2013)A special population of regulatory T cells potentiates muscle repair Cell 155 1282-1253
  • [7] Li J(2001)CD4+CD25high regulatory cells in human peripheral blood J Immunol 167 1245-1711
  • [8] Tan J(2006)CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells J Exp Med 203 1701-1061
  • [9] Martino MM(2019)One, no one, and one hundred thousand: T regulatory cells' multiple identities in neuroimmunity Front Immunol 10 2947-336
  • [10] Lui KO(2003)Control of regulatory T cell development by the transcription factor Foxp3 Science 299 1057-1443
12345678910